Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 484

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

Open access
Benayed, Ryma, Offin, Michael, Mullaney, Kerry, Sukhadia, Purvil, Rios, Kelly, Desmeules, Patrice, Ptashkin, Ryan, Won, Helen, Chang, Jason, Halpenny, Darragh, Schram, Alison M., Rudin, Charles M., Hyman, David M., Arcila, Maria E., Berger, Michael F., Zehir, Ahmet, Kris, Mark G., Drilon, Alexander, Ladanyi, Marc · 2019 · Clinical Cancer Research

Abstract

Purpose: Targeted next-generation sequencing of DNA has become more widely used in the management of patients with lung adenocarcinoma; however, no clear mitogenic driver alteration is found in some cases. We evaluated the incremental benefit of targeted RNA sequencing (RNAseq) in the identification of gene fusions and MET exon 14 (METex14) alterations in DNA sequencing (DNAseq) driver–negative lung cancers. Experimental Design: Lung cancers driver negative by MSK-IMPACT underwent further analysis using a custom RNAseq panel (MSK-Fusion). Tumor mutation burden (TMB) was assessed as a potential prioritization criterion for targeted RNAseq. Results: As part of prospective clinical genomic testing, we profiled 2,522 lung adenocarcinomas using MSK-IMPACT, which identified 195 (7.7%) fusions and 119 (4.7%) METex14 alterations. Among 275 driver-negative cases with available tissue, 254 (92%) had sufficient material for RNAseq. A previously undetected alteration was identified in 14% (36/254) of cases, 33 of which were actionable (27 in-frame fusions, 6 METex14). Of these 33 patients, 10 then received matched targeted therapy, which achieved clinical benefit in 8 (80%). In the 32% (81/254) of DNAseq driver–negative cases with low TMB [0–5 mutations/Megabase (mut/Mb)], 25 (31%) were positive for previously undetected gene fusions on RNAseq, whereas, in 151 cases with TMB >5 mut/Mb, only 7% were positive for fusions (P < 0.0001). Conclusions: Targeted RNAseq assays should be used in all cases that appear driver negative by DNAseq assays to ensure comprehensive detection of actionable gene rearrangements. Furthermore, we observed a significant enrichment for fusions in DNAseq driver–negative samples with low TMB, supporting the prioritization of such cases for additional RNAseq. See related commentary by Davies and Aisner, p. 4586

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-0225

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 484

Metadata

Authors
Benayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R., Won, H., Chang, J., Halpenny, D., Schram, A. M., Rudin, C. M., Hyman, D. M., Arcila, M. E., Berger, M. F., Zehir, A., Kris, M. G., Drilon, A., & Ladanyi, M.
Venue
Clinical Cancer Research
Published
2019-08-01
Volume
25
Issue
15
Pages
4712-4722
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2941103989
Cited by
484
References
66
FWCI
43.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0225
The paper
Benayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R., Won, H., Chang, J., Halpenny, D., Schram, A. M., Rudin, C. M., Hyman, D. M., Arcila, M. E., Berger, M. F., Zehir, A., Kris, M. G., Drilon, A., & Ladanyi, M. (2019). High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0225

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.